So if you read the Oregonian, by any chance, you really should look in the op-ed section today… because my article is there! 🙂 It’s also online at this link:
Oregon Needs a Right to Try Law
I’m so grateful to the Oregonian for printing this!! Of course, that having been said, it was PAINFUL to have to keep that piece to 500 words. There was SO, so much that I had to leave out– the gap between patients and experts, the crucial role of patients’ anger and sadness and frustration, the specific criticisms against Right to Try laws, their limitations and strengths, the entire history of Right to Try, many more details about exactly how the law is making it through the states and what might happen next, and so on and on and on and on!! Well, there will be more articles, believe me. 😉 For now, check this one out!
So… I’m working on an article about Right to Try laws from a patient’s point of view, and one of the best sources for research– on that subject or any other related to stem cells– is Paul Knoepfler’s blog. I check it pretty much every day. Today, there was an article about stem cell clinics. I’ll let you-all go over there and check it out, but I posted a comment that I kind of like. I’ve often heard the advice that if you write out a long comment on someone else’s blog, you really should publish it somewhere else, too. (For one thing, I can’t be absolutely sure it’ll make it through moderation.) So here it is– my take on stem cell clinics (for the day, anyway.)
BTW, I’m not a fan of them. At all. Sorry, I know some people have had good experiences, but I’m just Not. A. Fan. So that might come through a tad…
Here it is, and you don’t want to miss this one! The ending just might be my favorite bit so far.
In the brief break between speakers, I quickly looked over my notes about ALS. 8 out of 100,000 people were affected. There were many different phenotypes, some sporadic; some genetic; some caused by God only knew what. Even when ALS was familial, the specific genes involved were very difficult to pin down. Abnormal ones could occasionally be successfully targeted with success, but that was rare. There had been 160 treatment trials in the past 5 years, and out of those, only one effective drug had emerged, which was Riluzole.. And “effective” was a relative word in that case, to say the least.
Ocata does have a Wiki page, of course, but it needed a little updating. There’s a LOT that could potentially be added because so much exciting stuff has happened recently, and today I added the news about the official completion of Phase I/II and the EMA pivotal trial designation. There’s still a lot that could be done, but I’m really glad that the page exists in the first place. Go and take a look!
Here’s the Ocata page.